Login
$VOR
$18.83 -$0.14 (0.74%) After hours

$VOR SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 11, 2026, by and between Vor Biopharma Inc., a Delaware corporation (the “Company”), and RemeGen Co., Ltd. (the “Investor”).

05 Nov 2026 SCHEDULE 13G/A
04 Nov 2026 Form 4: Sokolove Jeremy Brett, Chief Medical Officer

Gave up 1,917 shares to cover exercise price or tax ($36.9K)

30 Oct 2026 424B5
30 Oct 2026 10-Q
05 Oct 2026 Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others

Received 500 shares by exercise or conversion ($6.4K)

04 Sep 2026 S-3ASR
26 Aug 2026 Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others

Received 1,500 shares by exercise or conversion ($5.6K)

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 SCHEDULE 13G/A
11 Aug 2026 10-Q
07 Aug 2026 SCHEDULE 13G/A
06 Aug 2026 SCHEDULE 13G
30 Jul 2026 SCHEDULE 13G
21 Jul 2026 SCHEDULE 13D/A
21 Jul 2026 Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others

Received 2,100,000 shares by exercise ($4.2K) · Sold 213 shares ($4.21K)

09 Jul 2026 Form 3: Zaccardelli David, Director

No securities owned

09 Jul 2026 Form 4: Zaccardelli David, Director

Granted 42,658 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support